MEDICINE CONTROLS METABOLIC SYNDROME And PRODUCES EMAGRECIMENTO COMBAT To The ABDOMINAL OBESIDADE 13 of June of 2005 (Bibliomed). Congress of the American Diabetes Association in San Diego was presented yesterday in 65º, California, plus a study involving the Rimonabant medicine (Acomplia ®, Sanofi-Aventis), that if it has shown efficient to help to control the obesidade in some clinical studies, besides being capable to collaborate in the suspension of the use of the tobacco. In the presented research, phase III of the study Diabetes RIVER (RIO-Rimonabant In Obesity) involved 1045 carrying patients of diabetes type 2 (diabetes of the adult). The study it analyzed the effect of the drug on the abdominal fat and the weight, on the glucose tax in the blood, on the arterial hipertensão, in the HDL cholesterol ("the good" call cholesterol) and in the dosage of triglicérides. The use of 20 mg of Rimonabant to the day, together with the control of diabetes with diet and medicines, was capable to reduce the weight in such a way as the abdominal circumference in approximately 50% of the patients who had received the remedy. It occurred still, after one year of use, an important reduction of the presence of the Metabolic Syndrome, with the reduction of the taxes of glucose and triglicérides, increase of the HDL, and reduction of the arterial hipertensão. The presence of the metabolic syndrome is associated with an appreciable increase of the mortality taxes, mainly for cardiovascular causes.
The Rimonabant acts in the endocanabinóide system, blocking receiving calls CB1, gifts in such a way in the nervous system as in the muscular, greasy cells, and of the liver, and is fruit of a long research that if it initiated in 1994, with the identification of these receivers. The presentation of the RIO-Diabetes study complements a series of divulged studies RIVER in last the two years; recently the RIO-Europe study, with excellent resulted of the Rimonabant in the control of the obesidade in not-diabetic patients it was published in the magazine The Lancet. The results of the study with the remedy had verified that dois-terços of that they had used it, together with a diet of control of calories, they had lost 5% of its corporeal weight, and that 40% of the volunteers had almost lost 10% of its weight. A significant reduction of the measure of the waist of the patients still occurred, together with a reduction in the cardiovascular factors of risk. The drug, that is being developed for the Sanofi-Aventis laboratory, functions blocking a receiver found in the brain, the greasy cells and other parts of the body, helping to regulate it the ingestion